# RMPT for Relapsed/Refractory Multiple Myeloma

> **NCT00961467** · PHASE2 · COMPLETED · sponsor: **Fondazione EMN Italy Onlus** · enrollment: 44 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Revlimid, Melphalan, Prednisone, Thalidomide
- **DRUG:** Revlimid, Melphalan, Prednisone, Thalidomide

## Key facts

- **NCT ID:** NCT00961467
- **Lead sponsor:** Fondazione EMN Italy Onlus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-03
- **Final completion:** 2016-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2016-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00961467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00961467, "RMPT for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00961467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*